Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy

Yoriko Yamashita, Y Yamashita
Japanese journal of clinical oncology · 2015 · vol. 45(5) , pp. 405–407 · doi:10.1093/jjco/hyu221 · PMID:25583423 · PMC4412138 · W2165166542
review OA: gold CC0 ⤵ 4 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

This review discusses the molecular characteristics and unsolved questions of ovarian clear cell carcinoma, including PI3CA mutation, ARID1a mutation, MET amplification, and its association with endometriosis, with a focus on future targeted therapies.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Until recently, ovarian clear cell carcinoma was recognized by its unique morphology and unfavorable patient outcome primarily due to tumor chemoresistance. Recently, specific molecular characteristics of ovarian clear cell carcinoma, such as PI3CA mutation, ARID1a mutation and MET amplification, have been elucidated. In addition, an association between endometriosis and the tumor has also been a focus of research in recent years. The aim of this review is to discuss the specificity and importance of molecular changes and various intriguing points that are not solved until today. Finally, future aspects, including hopes for the development of novel therapies, are discussed.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Endometriosis Nuclear Proteins Ovarian Neoplasms Ovarian Neoplasms Ovarian Neoplasms Ovarian Neoplasms Proto-Oncogene Proteins c-met Transcription Factors DNA-Binding Proteins Endometriosis Female Gene Amplification Humans Molecular Targeted Therapy Mutation Neoplasm Staging

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (50)

Cited by (4)

Source provenance

europepmc
last seen: 2026-06-13T06:22:48.782012+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:18:04.362919+00:00
License: CC0 · commercial use OK